{"name":"ITB-Med LLC","slug":"itb-med-llc","ticker":"","exchange":"","domain":"itbmedllc.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Mycophenolate Mofetil (MMF)","genericName":"Mycophenolate Mofetil (MMF)","slug":"mycophenolate-mofetil-mmf","indication":"Prevention of organ rejection in renal, cardiac, and hepatic transplant recipients","status":"marketed"},{"name":"Tacrolimus (TAC)","genericName":"Tacrolimus (TAC)","slug":"tacrolimus-tac","indication":"Prevention of organ rejection in transplant recipients (kidney, heart, liver, pancreas)","status":"marketed"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ATG","genericName":"ATG","slug":"atg","indication":"Prevention of acute organ rejection in renal transplant recipients","status":"marketed"}]}],"pipeline":[{"name":"ATG","genericName":"ATG","slug":"atg","phase":"marketed","mechanism":"ATG (Antithymocyte Globulin) is a polyclonal antibody that depletes T lymphocytes by binding to T-cell antigens and triggering their destruction.","indications":["Prevention of acute organ rejection in renal transplant recipients","Treatment of acute rejection episodes in renal transplant recipients","Aplastic anemia (severe)"],"catalyst":""},{"name":"Mycophenolate Mofetil (MMF)","genericName":"Mycophenolate Mofetil (MMF)","slug":"mycophenolate-mofetil-mmf","phase":"marketed","mechanism":"Mycophenolate mofetil is a prodrug that inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent organ rejection and treat autoimmune diseases.","indications":["Prevention of organ rejection in renal, cardiac, and hepatic transplant recipients","Active lupus nephritis","Autoimmune hemolytic anemia","Certain vasculitides and other autoimmune conditions"],"catalyst":""},{"name":"Tacrolimus (TAC)","genericName":"Tacrolimus (TAC)","slug":"tacrolimus-tac","phase":"marketed","mechanism":"Tacrolimus is a calcineurin inhibitor that suppresses T-cell activation by blocking the phosphatase calcineurin, preventing IL-2 production and T-cell proliferation.","indications":["Prevention of organ rejection in transplant recipients (kidney, heart, liver, pancreas)","Atopic dermatitis","Severe rheumatoid arthritis","Autoimmune uveitis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE4zNjNXbmNoeGQtWHNFOUd3ejM1UTgzOWVFUXNBZUd2LWhoNGxXUjVlWGdCaEZmSHE1ZUZJenppWWU1cTFnX2VrLS1zM2V4U3VSdjFXM1lqcHFUQVU3YVB2dWlJRThIQmVNUXBzUkZ5TlRTbW5QQ2NN?oc=5","date":"2025-02-07","type":"pipeline","source":"MedPage Today","summary":"First Gene-Edited Pig Kidney Functioned Until Recipient's Death - MedPage Today","headline":"First Gene-Edited Pig Kidney Functioned Until Recipient's Death","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQZHRESXlWM2JRMU54bjRWdjFsZjUybWV4YnFuRllXaWJkNHI0UVF2QWIzVC1Ub2RxWkJFT255OEh3X2loNDBsWXJBaV90bDhyMkN4eFduZDNLWXg3dU9Ia3A5TF96NUJhbFFXaVUxRk5Ea2pGWi0wVnlLeFVJYzVaek1zWlpIZXJobUJuV0pJemNHU3Z6eXJCSllOMlRCS1NMWUtRVnYwLUV0ZVdmVzFSeFI3UmVHdWgwem9TS1JrYw?oc=5","date":"2018-04-04","type":"trial","source":"Fierce Biotech","summary":"Buoyed by long-term organ transplant data, ITBMed bags $67M to advance ex-MedImmune asset - Fierce Biotech","headline":"Buoyed by long-term organ transplant data, ITBMed bags $67M to advance ex-MedImmune asset","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}